REGN - Regeneron's Dupixent COPD Sales To Reach $20B By 2026 Analyst Sees Larger Addressable Market | Benzinga
RBC Capital Markets analyst Brian Abrahams reiterated an Outperform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), raising the price forecast to $1,299 from $1,200.
Abrahams surveyed 31 pulmonologist physicians who see high volumes of COPD patients.
The analyst writes that the surveyed pulmonologists were excited about the ph.III data, the proportion of patients they view as having type 2 inflammation, and the expected rapidity of adoption post-approval all suggest dupixent’s COPD sales potential and contribution to near and long-term revenue are likely to be higher than even our bullish expectations.
The actual use ...